Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
The influence of diabetes on Parkinson’s progression
In recent research funded by Cure Parkinson’s, scientists have provided the strongest evidence to date that diabetes can affect the progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.
The 2022 Parkinson’s drug development pipeline report
The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.
Parkinson’s Clinical Study Group
Cure Parkinson’s is funding Professor Oliver Bandmann at the University of Sheffield to establish a nationwide infrastructure for a study group focused specifically on conducting clinical trials for Parkinson’s.
Phase 1a trial findings of iLCT prioritised drug, Anle138b
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps together in Parkinson’s.